Viking Therapeutics shares rise 10.04% intraday after HC Wainwright reiterates Buy rating and Phase III trial completion.

Viking Therapeutics (VKTX) rose 10.04% intraday following the completion of its Phase III VANQUISH-1 trial enrollment for obesity drug VK2735, which underscores strong market demand for its product. This development, coupled with HC Wainwright’s reiterated “Buy” rating and a $102 price target, reinforced investor confidence in the company’s pipeline. The rebound also coincided with bargain-hunting after a prior 42% selloff driven by mixed clinical data for VK2735, which had raised safety concerns. While recent trial-related volatility persisted, the positive momentum reflects optimism about VKTX’s competitive positioning in the obesity drug market and analysts’ favorable outlook.